Predictors of Major Adverse Limb Events After Endovascular Iliac Stenting: a Real-world Cohort Study

Peripheral arterial disease (PAD) involving the iliac arteries is a common manifestation of systemic atherosclerosis and represents a frequent cause of lifestyle-limiting intermittent claudication and chronic limb-threatening ischemia (CLTI). Over the past two decades, continuous advances in endovascular techniques, stent technology, and peri-procedural imaging have led to a progressive shift from open surgical reconstruction toward an endovascular-first strategy for the treatment of aortoiliac occlusive disease, including anatomically complex lesions classified as TransAtlantic Inter-Society Consensus II (TASC II) C and D.

Current international guidelines support endovascular treatment for most iliac lesions because of high technical success rates and lower perioperative morbidity compared with open surgical reconstruction. As a result, iliac artery stenting has become the predominant treatment modality in routine vascular practice. However, much of the available evidence is derived from selected patient populations or controlled clinical studies and may not fully reflect outcomes observed in unselected real-world cohorts with substantial comorbidity burden.

Although procedural success and vessel patency after iliac artery stenting have been widely reported, less information is available regarding predictors of clinically meaningful limb-related outcomes, particularly Major Adverse Limb Events (MALE). Furthermore, lesion morphology alone may not adequately explain variability in outcomes after technically successful revascularization. Patient-related factors, including frailty, chronic kidney disease, diabetes mellitus, coronary artery disease, and advanced age, may significantly influence post-procedural clinical trajectories. Frailty, assessed using the modified five-item Frailty Index (mFI-5), has been associated with adverse outcomes in cardiovascular and vascular surgical populations, but its prognostic role in patients undergoing iliac artery stenting remains insufficiently characterized.

This study is a single-center retrospective observational cohort study conducted at the Division of Vascular Surgery, IRCCS Galeazzi-Sant'Ambrogio Hospital, Milan, Italy. Consecutive adult patients who underwent endovascular stenting for de novo stenotic or occlusive disease of the common and/or external iliac arteries between January 2023 and May 2025 will be included. Clinical, anatomical, procedural, and follow-up data will be retrospectively extracted from institutional vascular registries, imaging databases, and electronic medical records.

The primary objective is to evaluate MALE-free survival following endovascular iliac artery stenting. Secondary objectives include assessment of primary patency, peri-procedural complications, target lesion revascularization, restenosis or occlusion, and all-cause mortality. The study will also evaluate associations between baseline clinical and anatomical characteristics and adverse limb outcomes, with particular attention to frailty as assessed by the mFI-5.

Follow-up data are derived exclusively from routine clinical surveillance, including outpatient evaluations, ankle-brachial index measurements when available, duplex ultrasound examinations, and additional imaging studies performed according to clinical indications. Outcomes will be analyzed using Kaplan-Meier survival methods and Cox proportional hazards regression models to identify factors associated with adverse clinical outcomes after iliac artery stenting in a real-world population.

• Primary Patency of the Treated Iliac Artery Segment [Time frame: 12 months]
• Number of Participants With Peri-Procedural Complications [Time frame: 30 days]
• All-Cause Mortality [Time frame: 12 months]
• Freedom From Target Lesion Revascularization (TLR) [Time frame: 12 months]
• Number of Participants With Iliac Artery Restenosis or Occlusion [Time frame: 12 months]